Last reviewed · How we verify

received an ossein-hydroxyapatite complex

University of Opole · FDA-approved active Small molecule

Ossein-hydroxyapatite complex provides bioavailable calcium and phosphate minerals along with organic bone matrix components to support bone mineralization and skeletal health.

Ossein-hydroxyapatite complex provides bioavailable calcium and phosphate minerals along with organic bone matrix components to support bone mineralization and skeletal health. Used for Osteoporosis prevention and treatment, Bone health supplementation.

At a glance

Generic namereceived an ossein-hydroxyapatite complex
SponsorUniversity of Opole
Drug classBone mineral supplement
ModalitySmall molecule
Therapeutic areaOrthopedics / Bone Health
PhaseFDA-approved

Mechanism of action

This complex combines hydroxyapatite (the inorganic mineral phase of bone) with ossein (the organic collagen-based matrix of bone), mimicking the natural composition of bone tissue. It is designed to be absorbed and incorporated into bone, promoting bone density and strength. The combination of mineral and organic components may enhance bioavailability and osteogenic activity compared to isolated mineral supplements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: